Liberty Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Liberty Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,765	Closed	-$221K	–	153
2022 Q1	$221K	Buy	+2,765	New	+$231K	0.08%	135
2021 Q4	–	Sell	-431	Closed	-$34K	–	281
2021 Q3	$34K	Buy	431 +278	+182%	+$21.9K	0.01%	501
2021 Q2	$13K	Sell	153 -3	-2%	-$238	0.01%	584
2021 Q1	$12K	Hold	156	–	–	0.01%	553
2020 Q4	$12K	Hold	156	–	–	0.01%	548
2020 Q3	$12K	Sell	156 -29	-16%	-$2.93K	0.01%	484
2020 Q2	$23K	Buy	185 +5	+3%	+$497	0.02%	356
2020 Q1	$15K	Sell	180 -13	-7%	-$1.12K	0.01%	398
2019 Q4	$16K	Buy	193 +10	+5%	+$755	0.01%	443
2019 Q3	$12K	Sell	183 -12	-6%	-$924	0.01%	481
2019 Q2	$16K	Buy	195 +54	+38%	+$4.62K	0.01%	444
2019 Q1	$12K	Buy	141 +22	+18%	+$2.04K	0.01%	405
2018 Q4	$10K	Buy	+119	New	+$11.3K	0.01%	421

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Liberty Wealth Management's BMRN Position: Q2 2022 in Review

Liberty Wealth Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 2,765 shares — an estimated $221K sold.

Liberty Wealth Management first reported a position in BMRN in Q4 2018 and held it in 13 quarters. The position peaked at $221K in Q1 2022. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Liberty Wealth Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Liberty Wealth Management sold 2,765 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $221K.
Liberty Wealth Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 13 quarters.
Liberty Wealth Management's BioMarin Pharmaceuticals position peaked at $221K in Q1 2022.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Liberty Wealth Management's 13F filing for Q2 2022, filed 15 Aug 2022.